health
1 min read
Eli Lilly Drug Retatrutide Shows Weight Loss in Type 2 Diabetes Trial
Eli Lilly's experimental drug retatrutide led to notable weight reduction in individuals with Type 2 diabetes, according to new trial results. Participants in the study, published in The Lancet, experienced an average loss of up to 60 pounds.
09/30/2026 · Connecticut edition
Advertisement
Advertisement
Why it matters locally: For the approximately 342,000 adults in Connecticut diagnosed with diabetes, the promising results of Eli Lilly's experimental drug retatrutide offer a potential new treatment option for managing weight associated with Type 2 diabetes.
Eli Lilly's experimental drug retatrutide led to significant weight loss among individuals with Type 2 diabetes. Participants in a late-stage clinical trial lost up to 60 pounds, which represented approximately 23% of their body weight. Researchers published the findings from the study in The Lancet on Tuesday. The results detail the effects of retatrutide, a GLP-1 receptor agonist, in individuals diagnosed with Type 2 diabetes.Related Topics
Editorial Transparency
AI-Generated · Written by National DeskArticle Ratings
Factual
0.0
Likeable
0.0
Bias
0.0
Objective
0.0
How do you feel about this story?
NA
National Desk
Trust 3.1101191 articles8,256,373 views75% fact accuracy
View ProfileSign in to follow this author from their profile.
Discussion (0)
Join the Conversation
Join the conversation
Sign in to share your thoughts, reply to readers, and like comments.
No comments yet. Be the first to comment!